Arcadia Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Arcadia Biosciences, Inc. (RKDA) on April 3, 2026, covering events occurring on March 30, 2026. The filing addresses a change in the Company's independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the current period. However, it references the Company's Annual Report on Form 10-K (filed March 26, 2026), which disclosed an accumulated deficit, recurring net losses, and net cash used in operations. These factors contributed to an explanatory paragraph in prior audit reports regarding the Company's ability to continue as a going concern.
Material Changes
- Dismissal of Auditor: On March 30, 2026, the Audit Committee dismissed Deloitte & Touche LLP as the independent registered public accounting firm.
- Engagement of New Auditor: The Audit Committee approved the engagement of Ramirez Jimenez International CPAs ("RJI") effective immediately to review the quarter ending March 31, 2026, and audit the year ending December 31, 2026.
- Internal Control Weaknesses: The Company identified material weaknesses in internal control over financial reporting as of December 31, 2025. These stem from insufficient segregation of duties and insufficient information system controls, exacerbated by reduced employee headcount.
Outlook, Risks, and Management Commentary
Management confirmed there were no disagreements with Deloitte regarding accounting principles or auditing scope during the two most recent fiscal years, other than the reportable event concerning internal control weaknesses. The filing notes that resources may not be sufficient to meet anticipated cash requirements, reinforcing the going concern risk previously disclosed. No specific financial guidance or future outlook was provided in this document.
Investor Verification Checklist
- Verify the specific details of the material weaknesses in internal controls disclosed in the Form 10-K filed on March 26, 2026.
- Review the letter from Deloitte & Touche LLP (Exhibit 16.1) to confirm their agreement with the Company's statements regarding the dismissal.
- Assess the Company's current cash runway and capital raising plans given the disclosed going concern risks.
- Monitor the transition process between Deloitte and RJI for any potential delays in future financial reporting.